Sugi Predict

Sugi Predict / Compounds / SCHEMBL11997430

SCHEMBL11997430

SCHEMBL11997430

CO[C@H]1OC(COS(=O)(=O)O)[C@@H](O[C@H]2C[C@H](O)[C@@H](OC3OC(COS(=O)(=O)O)[C@@H](O[C@H]4C[C@H](O)C(O[C@@H]5OC(COS(=O)(=O)O)[C@@H](O[C@H]6C[C@H](O)[C@H](O)CO6)[C@H](O)C5N)CO4)[C@H](O)C3N)CO2)[C@H](O)C1N

nearest known ligand 0.35

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ FGF1 P05230 5/20 0.35
▸ F10 P00742 3/20 0.33
▸ SERPINC1 P01008 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HPSE Q9Y251 2/20 0.32
▸ FGF2 P09038 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11921944 1.00 FGF1 (0.35) FGF1F10SERPINC1BLMRECQL
SCHEMBL11997463 1.00 FGF1 (0.35) FGF1F10SERPINC1BLMRECQL
SCHEMBL11997483 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11921934 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11921923 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11997478 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11997469 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11997485 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11921938 0.96 BLM (0.38) FGF1BLMRECQLTDP1
SCHEMBL11921942 0.96 BLM (0.38) FGF1BLMRECQLTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012413-B2 FGF receptor-activating N-acyl octasaccharides, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-04-21 — — US disclosed
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-08-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214754-A1 FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF FGFR1, FGF2, FGFR3 FGF1 5/4885F10 597/4885SERPINC1 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback